Venmax drugs & pharmaceuticals Limited has submitted its quarterly compliance certificate to BSE Limited, confirming adherence to SEBI (Depositories and Participants) Regulations for the quarter ended March 31, 2026. The submission was made on April 14, 2026, as part of the company's regulatory obligations.

Regulatory Compliance Details

The compliance certificate was filed pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. This regulation mandates companies to provide confirmation regarding their compliance with depositories-related requirements on a quarterly basis.

Certificate Issuance and Verification

The compliance certificate was issued by CIL Securities Limited, which serves as the Registrar and Share Transfer Agent (RTA) for Venmax Drugs & Pharmaceuticals Limited. CIL Securities Limited confirmed that securities received from Depository Participants for dematerialization during the quarter ended March 31, 2026, were properly processed and confirmed to the depositories.

The RTA also verified that:

• Securities comprised in the certificates have been listed on stock exchanges where the company's earlier issued securities are listed
• Security certificates received for dematerialization have been mutilated and cancelled after due verification
• Names of depositories have been substituted in the Register of Members as registered owners within the stipulated time period

Corporate Communication

The submission was made by Priyanka Agarwal, Company Secretary & Compliance Officer of Venmax Drugs & Pharmaceuticals Limited. The communication was digitally signed and timestamped on April 14, 2026, at 12:29:13 +05'30', ensuring proper authentication and record-keeping.

Company Background

Venmax Drugs & Pharmaceuticals Limited, formerly known as Yenkey Drugs & Pharmaceuticals Ltd, operates from Nama Chemicals Industries in Hyderabad, Telangana. The company maintains its registered office at IDA Cherlapally and continues to fulfill its regulatory obligations as a listed entity on Indian stock exchanges.

Venmax drugs & pharmaceuticals Limited has filed its mandatory annual declaration with BSE confirming that promoters have not encumbered any shares during the financial year ended March 31, 2026. The disclosure was made under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Regulatory Compliance Declaration

The company submitted the declaration on April 6, 2026, through Company Secretary and Compliance Officer Priyanka Agarwal. The filing confirms that the promoters and promoter group have maintained their shareholdings without any encumbrance throughout the financial year.

Promoter Share Declaration

Promoter Venkat Narender Nuka provided a specific declaration regarding his shareholding in the company. His disclosure was addressed to both BSE and the company's Audit Committee, ensuring comprehensive regulatory compliance.

Regulatory Framework

The SEBI (Substantial Acquisition of Shares and Takeovers) Regulations mandate annual declarations from promoters to ensure transparency in shareholding patterns. Under Regulation 31(4), promoters must declare any encumbrance on their shares, while Regulation 31(5) requires disclosure of changes in encumbrance status.

The declaration serves as a compliance measure to maintain market transparency and protect investor interests. Both the company and individual promoter have fulfilled their regulatory obligations by confirming no encumbrance was created on promoter shares during the specified period.